Paper Details

  1. Home
  2. Paper Details

Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets.

Author: KoldSøren, PaludanCarl Gustaf, RahbekOle, ThomsenKristoffer Koed Vittrup

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A new medication called Burosumab is available for children with severe X-linked hypophosphatemia (XLHR), a condition that weakens bones. This study investigates the complications associated with traditional surgical treatments for XLHR, as there has been limited research on the impact of surgery and complications in this patient group.
Paper Details　
Original Abstract of the Article :
XLHR in children with a Rickets Severity Score ≥2 can now be treated with the new antibody drug, Burosumab, which prevents bone deformities and increases gait endurance. This study illustrates the extent of complications in the traditional orthopedic treatment of XLHR. The impact of surgery and seve...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1515/jpem-2021-0775

データ提供：米国国立医学図書館（NLM）

X-Linked Hypophosphatemic Rickets: A Desert of Orthopedic Challenges

This research explores the orthopedic challenges faced by individuals with X-linked hypophosphatemic rickets (XLHR), a complex condition that can lead to significant bone deformities. The authors, like skilled desert engineers, delve into the complexities of [research focus], utilizing a [research method] to assess the impact of traditional orthopedic treatment on individuals with XLHR. Their research provides valuable insights into the challenges and complications associated with this condition, highlighting the need for innovative approaches to treatment.

A Shifting Landscape of Treatment

The study found [key findings], underscoring the need for a comprehensive approach to XLHR management. This research provides valuable insights into the complexities of treating this condition, paving the way for a more effective and personalized approach.

A Desert Oasis of Innovation

This research emphasizes the importance of [recommendations for action] to improve outcomes for individuals with XLHR. It's like finding a hidden oasis in the vast and often challenging desert of XLHR treatment, offering a glimpse into a future where innovative therapies can provide better outcomes for patients.

Dr.Camel's Conclusion

X-linked hypophosphatemic rickets is a complex condition that can have significant implications for bone health and overall well-being. This research provides valuable insights into the challenges and complications associated with traditional orthopedic treatment, highlighting the need for innovative approaches and personalized care. It's like finding a wellspring of hope in the desert of XLHR treatment, offering a path towards a future where patients can live healthier and more fulfilling lives.

Date :
  1. Date Completed 2022-08-12
  2. Date Revised 2022-08-12
Further Info :

Pubmed ID

35700440

DOI: Digital Object Identifier

10.1515/jpem-2021-0775

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.